Drug Profile
Research programme: gliadin protein therapeutics - Diamyd Medical
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Unknown
- Developer Diamyd Medical AB
- Class Proteins
- Mechanism of Action Gliadin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coeliac disease; Type 1 diabetes mellitus
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Coeliac disease in Sweden (Intranasal)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in Sweden (Intranasal)
- 31 Aug 2015 Diamyd Medical licenses a drug candidate from undisclosed inventors, for the treatment of type I diabetes and coeliac disease